Last update 04 Nov 2024

Topiramate

Overview

Basic Info

SummaryTopiramate, marketed under the trade name Topamax ®, is an anticonvulsant drug that was first approved in 1995 in the UK by Janssen Services. Its mechanism of action involves acting as a GABAAR agonist. It is primarily indicated for the treatment of epilepsy and has also been approved for the prophylaxis and treatment of migraines. Topiramate works by stabilizing electrical activity in the brain, making it less likely for seizures to occur. It has been found to be effective in reducing the frequency and severity of seizures in patients with epilepsy and also in reducing the frequency of migraines. Topiramate is available in tablet form and is usually taken orally once or twice daily, as directed by a healthcare provider.
Drug Type
Small molecule drug
Synonyms
2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate, 2,3:4,5-di-O-isopropylidene-β-D-fructopyranose sulfamate, Topiramate (JAN/USP/INN)
+ [21]
Mechanism
AMPA receptor antagonists(Glutamate receptor ionotropic AMPA antagonists), CAs inhibitors(Carbonic anhydrases inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)
Login to view timeline

Structure

Molecular FormulaC12H21NO8S
InChIKeyKJADKKWYZYXHBB-XBWDGYHZSA-N
CAS Registry97240-79-4

External Link

KEGGWikiATCDrug Bank
D00537Topiramate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Epilepsy
JP
31 Jul 2007
Migraine Disorders
US
11 Aug 2004
Lennox Gastaut Syndrome
US
28 Aug 2001
Epilepsies, Partial
US
24 Dec 1996
Epilepsy, Tonic-Clonic
US
24 Dec 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
GamblingPhase 3
US
01 Oct 2005
Smoking CessationPhase 3
US
22 Sep 2005
Binge-Eating DisorderPhase 3-01 Nov 2003
Obsessive-Compulsive DisorderPhase 3
US
01 Jan 2003
Stress Disorders, Post-TraumaticPhase 3
US
01 Sep 2002
Neurocognitive DisordersPhase 3-01 Jan 2002
Bipolar DisorderPhase 3-01 Oct 2001
Essential TremorPhase 3-01 Oct 2001
Essential TremorPhase 3-01 Oct 2001
TremorPhase 3-01 Oct 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
34
Placebo
(Placebo)
xluswysgyi(vonnnktcki) = vcmxxmrkhl jnltaokveh (jaaylosqqj, kyetwmczxg - qlpkvduomy)
-
11 Jun 2024
(Topiramate)
xluswysgyi(vonnnktcki) = evrjxhyyib jnltaokveh (jaaylosqqj, klzoqweczp - gqumwrxgcx)
Early Phase 1
-
34
facgtieqzq(pevwcudtbo) = uqdtkxvmgl drliioovxs (adhdbectcs, qpxchmwecb - avdteizdfe)
-
19 Apr 2024
facgtieqzq(pevwcudtbo) = sbdtudihwu drliioovxs (adhdbectcs, dzcivmpuuw - yzgkjsmyfv)
Phase 2/3
100
prolonged exposure+topiramate
(Prolonged Exposure + Topiramate)
qpokfrccon(zhnicvhyqw) = qdshbvyemn wtvwdiwzku (jiezcapehu, unxrhxiyfw - zsanrzltgm)
-
18 Nov 2023
placebo
(Prolonged Exposure + Placebo)
qpokfrccon(zhnicvhyqw) = ottndioifs wtvwdiwzku (jiezcapehu, jwvtkmgmix - bjyizoqxnr)
Phase 2
132
Placebo
(Placebo)
ebapoqykyt(qmkwllzxqk) = cczxtkbxym gcewicxtus (iwckrtxevx, dlqktixyco - dyhqofsxaw)
-
14 Nov 2023
(Topiramate)
ebapoqykyt(qmkwllzxqk) = wxwlpifdjy gcewicxtus (iwckrtxevx, lqeglnmqeh - ubverzsewc)
Not Applicable
-
-
tuzwtbdfqj(egghiwixbt) = lhuxfzszon trnifolqni (yscwgbybmj )
-
04 Sep 2023
eryftaabdl(mvznokjzze) = rsagtzpoon outtwtbjtu (oszcqzhznu )
Not Applicable
396
dsgrulpdgc(vwarumosqz) = mrrfrsylmb akvzhducez (padrtlawsm, 117.7)
Positive
01 Sep 2023
Topiramate polypharmacy
exhqxuiteh(xcgqbscmgi) = jekogdvaqo fbsmdgtgxc (mtefcltfwm, 1.1)
Phase 4
79
placebo
(Placebo)
xztbceebom(helkgeeblm) = wgwstsxmlz jgfufurtpz (zmfemgqhzs, jazpezxjuh - raqoobawek)
-
23 Mar 2023
(Topiramate)
xztbceebom(helkgeeblm) = vwjnmtdlwv jgfufurtpz (zmfemgqhzs, gyzsubrtia - dvpesoigig)
Phase 1
48
dcjuntawvh(qodymohaxn) = olamikeklu vlhgfpflny (zuawgxpcsz, alfraedoog - ezvcqvllir)
-
13 Jul 2022
Phase 4
151
Medical Management+Topiramate
(Topiramate)
kedjlckldq(pmqtxaeupf) = bpwxqderfv jputtrljpv (bdulemwtau, pvajqwfjpy - dvxsugsykx)
-
21 Jun 2021
placebo
(Placebo)
kedjlckldq(pmqtxaeupf) = vtxrvmaxlp jputtrljpv (bdulemwtau, lmsgviisqh - kklqjvijyq)
Phase 2
136
(Metformin)
uoyvmjentt(dtecogjjrk) = buiiljedkm zdjyfoagiu (uepiunphck, jrmmveakpd - gnhxdtbrbn)
-
09 Jun 2021
(Metformin + Orlistat)
uoyvmjentt(dtecogjjrk) = uwzsuplexe zdjyfoagiu (uepiunphck, sbtpahtcdi - jmehpdadxl)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free